Dexcom (NASDAQ:DXCM) is scheduled to post its quarterly earnings results after the market closes on Monday, April 30th. Analysts expect Dexcom to post earnings of ($0.28) per share for the quarter.
Dexcom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, February 27th. The medical device company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million for the quarter, compared to analyst estimates of $217.82 million. Dexcom had a negative net margin of 6.99% and a negative return on equity of 13.99%. On average, analysts expect Dexcom to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Dexcom stock opened at $72.47 on Monday. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78. Dexcom has a twelve month low of $42.62 and a twelve month high of $81.91.
In related news, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $73.04, for a total transaction of $730,400.00. Following the completion of the sale, the insider now directly owns 521,674 shares of the company’s stock, valued at approximately $38,103,068.96. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $54.67, for a total transaction of $89,385.45. Following the sale, the executive vice president now directly owns 65,049 shares of the company’s stock, valued at $3,556,228.83. The disclosure for this sale can be found here. Insiders sold 35,854 shares of company stock valued at $2,302,881 over the last three months. Insiders own 1.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Dexcom (DXCM) Set to Announce Earnings on Monday” was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2018/04/23/dexcom-dxcm-set-to-announce-earnings-on-monday.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.